ArticleMolecular therapy. Oncology2026

Interleukin-15-armored ALPPL2 CAR T cells demonstrate robust preclinical efficacy for solid tumors.

Junquan Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.